FDA Announces Accelerated Approval for Alzheimer’s Drug

June 14, 2021 / Nueterra Capital Marketing

The FDA announced that it has granted accelerated approval for Aduhelm, a drug that purports to slow the development of Alzheimer’s disease.

In Alzheimer’s patients, abnormal levels of a naturally occurring but potentially toxic protein form amyloid beta plaque between neurons and disrupts cell function. According to the FDA release and the Alzheimer’s Association, Aduhelm works by reducing the amount of amyloid beta plaque, thereby slowing progression of mild cognitive impairment (MCI) due to Alzheimer’s disease and early Alzheimer’s dementia.

This significant development was hailed by Nueterra Capital portfolio company BrainCheck, whose CORTEXTM technology platform helps clinicians detect cognitive impairment earlier so patients can receive a diagnosis and begin the appropriate treatments.